Biotech: Down for the Count

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-03-01-2001, Volume 0, Issue 0

Stirling, UK-Scotia became the first public UK biotechnology company to seek protection from creditors after the European Medicines Evaluation Agency rejected Foscan (temoporfin), the anticancer agent on which its fortunes were pinned.